Latest Vivus Inc (VVUS) Headlines
Vivus Down 29.1% Since SmarTrend Downtrend Call (VVUS)
Comtex SmarTrend(R) - Fri Mar 07, 9:15AM CST
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 1 month, Vivus has returned 29.09% as of today's recent price of $6.13.
The Zacks Analyst Blog Highlights:InterMune, Alexion, Regeneron, VIVUS and Arena
PR Newswire - Thu Mar 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the InterMune (Nasdaq:ITMN-Free Report), Alexion (Nasdaq:ALXN-Free Report), Regeneron (Nasdaq:REGN-Free Report), VIVUS (Nasdaq:VVUS-Free Report) and Arena (Nasdaq:ARNA-Free Report).
2 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 05, 5:00AM CST
Keep these under-$10 biotech stocks on your radar.
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Auxilium Pharma Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:00AM CST
Revenues were boosted by the recently acquired subsidiary, Actient, as well as higher Xiaflex sales in the U.S.
3 Important Investing Lessons From the Oscars
David Williamson, The Motley Fool - Motley Fool - Sun Mar 02, 7:10PM CST
Football season is over, which means my wife regained control of our TV remote. This also means, like millions of Americans, I will be watching the 86th Academy Awards tonight. While my taste in film is decidedly more Pacific Rim than Precious ,...
Arena Pharmaceuticals, Inc. Down for No Reason
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 8:19PM CST
Arena Pharmaceuticals ended down 3.8% Friday after announcing earnings on Thursday night that included a rather paltry $2.3 million in revenue from sales of its obesity drug Belviq. The sales don't seem to justify the downturn. We've known about...
Activist Investors Agitating Biotechs Bring Multi-Bagger Returns
David Williamson, The Motley Fool - Motley Fool - Fri Feb 28, 6:05PM CST
Activist investors have garnered increasing attention, as they try to bend health-care company management to focus on maximizing shareholder value.These proxy fights are important for investors, especially in biotech, where buyouts are the preferred...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Auxilium Q4 Beats Estimates, But Guidance Cautious
at Investor's Business Daily - Fri Feb 28, 9:42AM CST
Auxilium Pharmaceuticals (AUXL) beat analysts' Q4 expectations but guided in line Friday morning. Auxilium shares were up more than 2% in early trading in the stock market today, hitting its highest point since May 2010. Revenue totaled $125.9...
Shares of VVUS Down 32.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 27, 4:53PM CST
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 1 month, Vivus has returned 32.79% as of today's recent price of $5.81.
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 11:01PM CST
Arena Pharmaceuticals will release its quarterly report on Thursday, and investors are more nervous than ever about the prospects for the maker of obesity drug Belviq. With rival VIVUS having reported another round of disappointing sales of its...
Why SINA, VIVUS, and Tenet Healthcare Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 7:30PM CST
Stocks finished narrowly lower on Tuesday, as investors seemed content with the impressive gains they've scored so far this month after a terrible January. Yet even though broad market benchmarks fell only a fraction of a percent, much larger losses...
Another Big Failure for VIVUS, Inc.
David Williamson, The Motley Fool - Motley Fool - Tue Feb 25, 4:02PM CST
Vivus Pharmaceuticals is having an absolutely awful day, with the stock down more than 13% after the company reported its Q4 results. The launch of its first-in-class obesity drug Qsymia was very highly anticipated among investors with the market...
Why VIVUS Inc. Shares Slimmed Down
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
Why Vivus (VVUS) Is Down Today
at The Street - Tue Feb 25, 9:47AM CST
Vivus (VVUS) falls despite the pharmaceutical company's report of fourth-quarter earnings that beat analysts' expectations. The company reported a net loss of 17 cents a share, which was much narrower than the Zacks consensus estimate of 43 cents and...
Narrower-than-Expected Loss at VIVUS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 9:30AM CST
VIVUS Inc. reported fourth quarter 2013 loss of 9 cents.
Why VIVUS Inc. Is Falling Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 25, 8:33AM CST
VIVUS reported earnings after the bell yesterday and its shares have been on a roller coaster ride ever since. Immediately following the release, shares rose over 4%, but have now fallen close to 13% in premarket trading this morning. ...
Health & Nutritional Stocks in the News - Company Expands Product Diversity Based on Growing Consumer Demand
PR Newswire - Tue Feb 25, 8:00AM CST
Consumer goods & bio/pharma companies draw attention from investors with increased production and news developments: RiceBran Technologies (NASDAQ: RIBT), Mondelez International, Inc. (NASDAQ: MDLZ), Whole Foods Market, Inc. (NASDAQ: WFM), Inovio Pharmaceuticals, Inc. (NYSE: INO) and VIVUS Inc. (NASDAQ: VVUS)
Vivus Down 29.1% Since SmarTrend Downtrend Call (VVUS)
Comtex SmarTrend(R) - Fri Mar 07, 9:15AM CST
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 1 month, Vivus has returned 29.09% as of today's recent price of $6.13.
The Zacks Analyst Blog Highlights:InterMune, Alexion, Regeneron, VIVUS and Arena
PR Newswire - Thu Mar 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the InterMune (Nasdaq:ITMN-Free Report), Alexion (Nasdaq:ALXN-Free Report), Regeneron (Nasdaq:REGN-Free Report), VIVUS (Nasdaq:VVUS-Free Report) and Arena (Nasdaq:ARNA-Free Report).
2 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 05, 5:00AM CST
Keep these under-$10 biotech stocks on your radar.
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Auxilium Pharma Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:00AM CST
Revenues were boosted by the recently acquired subsidiary, Actient, as well as higher Xiaflex sales in the U.S.
3 Important Investing Lessons From the Oscars
David Williamson, The Motley Fool - Motley Fool - Sun Mar 02, 7:10PM CST
Football season is over, which means my wife regained control of our TV remote. This also means, like millions of Americans, I will be watching the 86th Academy Awards tonight. While my taste in film is decidedly more Pacific Rim than Precious ,...
Arena Pharmaceuticals, Inc. Down for No Reason
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 8:19PM CST
Arena Pharmaceuticals ended down 3.8% Friday after announcing earnings on Thursday night that included a rather paltry $2.3 million in revenue from sales of its obesity drug Belviq. The sales don't seem to justify the downturn. We've known about...
Activist Investors Agitating Biotechs Bring Multi-Bagger Returns
David Williamson, The Motley Fool - Motley Fool - Fri Feb 28, 6:05PM CST
Activist investors have garnered increasing attention, as they try to bend health-care company management to focus on maximizing shareholder value.These proxy fights are important for investors, especially in biotech, where buyouts are the preferred...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Auxilium Q4 Beats Estimates, But Guidance Cautious
at Investor's Business Daily - Fri Feb 28, 9:42AM CST
Auxilium Pharmaceuticals (AUXL) beat analysts' Q4 expectations but guided in line Friday morning. Auxilium shares were up more than 2% in early trading in the stock market today, hitting its highest point since May 2010. Revenue totaled $125.9...
Shares of VVUS Down 32.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 27, 4:53PM CST
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 1 month, Vivus has returned 32.79% as of today's recent price of $5.81.
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 11:01PM CST
Arena Pharmaceuticals will release its quarterly report on Thursday, and investors are more nervous than ever about the prospects for the maker of obesity drug Belviq. With rival VIVUS having reported another round of disappointing sales of its...
Why SINA, VIVUS, and Tenet Healthcare Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 7:30PM CST
Stocks finished narrowly lower on Tuesday, as investors seemed content with the impressive gains they've scored so far this month after a terrible January. Yet even though broad market benchmarks fell only a fraction of a percent, much larger losses...
Another Big Failure for VIVUS, Inc.
David Williamson, The Motley Fool - Motley Fool - Tue Feb 25, 4:02PM CST
Vivus Pharmaceuticals is having an absolutely awful day, with the stock down more than 13% after the company reported its Q4 results. The launch of its first-in-class obesity drug Qsymia was very highly anticipated among investors with the market...
Why VIVUS Inc. Shares Slimmed Down
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
Why Vivus (VVUS) Is Down Today
at The Street - Tue Feb 25, 9:47AM CST
Vivus (VVUS) falls despite the pharmaceutical company's report of fourth-quarter earnings that beat analysts' expectations. The company reported a net loss of 17 cents a share, which was much narrower than the Zacks consensus estimate of 43 cents and...
Narrower-than-Expected Loss at VIVUS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 9:30AM CST
VIVUS Inc. reported fourth quarter 2013 loss of 9 cents.
Why VIVUS Inc. Is Falling Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 25, 8:33AM CST
VIVUS reported earnings after the bell yesterday and its shares have been on a roller coaster ride ever since. Immediately following the release, shares rose over 4%, but have now fallen close to 13% in premarket trading this morning. ...
Health & Nutritional Stocks in the News - Company Expands Product Diversity Based on Growing Consumer Demand
PR Newswire - Tue Feb 25, 8:00AM CST
Consumer goods & bio/pharma companies draw attention from investors with increased production and news developments: RiceBran Technologies (NASDAQ: RIBT), Mondelez International, Inc. (NASDAQ: MDLZ), Whole Foods Market, Inc. (NASDAQ: WFM), Inovio Pharmaceuticals, Inc. (NYSE: INO) and VIVUS Inc. (NASDAQ: VVUS)
